Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 856866-72-3 Chemical Structure| 856866-72-3

Structure of Tedizolid
CAS No.: 856866-72-3

Chemical Structure| 856866-72-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tedizolid is an oxazolidinone-class antibiotic used to treat for acute bacterial skin and skin structure infections, working by inhibition of protein synthesis by binding to the 50S ribosomal subunit of the bacteria.

Synonyms: DA-7157; Torezolid

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Buschfort, Friederike ;

Abstract: Severe sepsis and septic shock are among the most urgent problems of modern medicine, accounting for 20-80% of illnesses and a mortality rate of 22-76% in ICU patients. The joint project "DiabKON" (Diagnostic Therapy Control), from which this dissertation emerged, attempts to improve the treatment of intensive care patients through controlled therapy. The focus is on therapy monitoring, in which a renewed administration of antibiotics should depend on the timely determination of the concentration in the patient's blood. The project was funded by the German Federal Ministry of Education and Research under the funding measure "KMU-innovativ: Medizintechnik" (FKZ 13GW0354 A-F). The aim of this work was to establish immunoassays that allow the rapid, cost-effective and quantitative determination of the antibiotics and from human blood samples. The results of the two immunoassays should be comparable with the reference method LC-MS/MS. To this end, monoclonal antibodies were first generated by immunizing mice with the antibiotics bound to carrier proteins. Spleen cells from mice with the highest antibody titer were then fused with myeloma cells to form hybridoma cells. Selection of the best positive clones was then performed by direct competitive ELISA over multiple rounds of screening. Assay development for and included optimization of the assay procedure with testing of multiple assay formats and establishment of a standard curve for quantitative detection. Optimization of the reagents used also significantly improved the stability of the assay and thus the reliability of the measurement. Following development, verification and validation of the two tests enabled all the required performance parameters of the assays to be determined. It was found that both assays met all regulatory requirements in terms of accuracy, analytical sensitivity, stability and reproducibility. The method comparisons showed very good comparability to the reference method LC-MS/MS. Both tests can be performed fully automatically on the DRG:HYBRiD-XL instrument from DRG Instruments GmbH. They are used for rapid quantitative detection of concentrations of and in the blood and thus allow close and timely control of therapy. The findings of this work contribute to the development of further tests against commonly used , which can then be used for therapy monitoring of treatment.

Purchased from AmBeed:

Alternative Products

Product Details of Tedizolid

CAS No. :856866-72-3
Formula : C17H15FN6O3
M.W : 370.34
SMILES Code : O=C1O[C@@H](CO)CN1C2=CC=C(C3=CC=C(C4=NN(C)N=N4)N=C3)C(F)=C2
Synonyms :
DA-7157; Torezolid
MDL No. :MFCD19442562
InChI Key :XFALPSLJIHVRKE-GFCCVEGCSA-N
Pubchem ID :11234049

Safety of Tedizolid

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H228-H315-H319
Precautionary Statements:P240-P210-P241-P264-P280-P302+P352-P370+P378-P337+P313-P305+P351+P338-P362+P364-P332+P313
Class:4.1
UN#:1325
Packing Group:

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01431833 Hepatic Impairment Phase 1 Completed - United States, Florida ... More >> Trius Investigator Site 001 Orlando, Florida, United States, 32809 United States, Minnesota Trius Investigator Site 002 Minneapolis, Minnesota, United States, 55404 Less <<
NCT02097043 Healthy Phase 1 Completed - Korea, Republic of ... More >> Seoul National University Hospital Seoul, Korea, Republic of Less <<
NCT00761215 Skin Diseases, Infectious ... More >> Skin Diseases, Bacterial Less << Phase 2 Completed - United States, Alabama ... More >> Trius Study Site #011 Dothan, Alabama, United States, 36301 United States, California Trius Study site #001 Chula Vista, California, United States, 91911 Trius Study Site #009 Long Beach, California, United States, 92708 Trius Study site #002 Oceanside, California, United States, 92056 Trius Study site #010 Pasadena, California, United States, 91105 Trius Study site 007 San Francisco, California, United States, 94143 Trius Study site 003 San Jose, California, United States, 95124 United States, Georgia Trius Study site 004 Columbus, Georgia, United States, 31904 Trius Study site #006 Ludowici, Georgia, United States, 31316 Trius Study site #005 Savannah, Georgia, United States, 31406 United States, Illinois Trius Study site #012 Springfield, Illinois, United States, 62701 United States, Michigan Trius study sie #008 Detroit, Michigan, United States, 48202 Less <<
NCT00761215 - Completed - -
NCT00671814 Healthy Subjects Phase 1 Completed - United States, Wisconsin ... More >> Covance Clinical Research Unit Madison, Wisconsin, United States, 53704 Less <<
NCT01421511 - Completed - -
NCT00671359 Healthy Phase 1 Completed - United States, California ... More >> Covance CRU San Diego, California, United States, 92123 Less <<
NCT01156077 Bacterial Infection Phase 1 Completed - -
NCT01442831 Healthy Phase 1 Completed - United States, Wisconsin ... More >> Trius Investigator Site 001 Madison, Wisconsin, United States, 53704 Less <<
NCT01452828 Renal Impairment Phase 1 Completed - United States, Florida ... More >> Trius Investigator Site 001 Orlando, Florida, United States, 32809 United States, Minnesota Trius Investigator Site 002 Minneapolis, Minnesota, United States, 55404 Less <<
NCT01421511 Skin and Subcutaneous Tissue B... More >>acterial Infections Less << Phase 3 Completed - -
NCT01461460 Healthy Volunteer Phase 1 Completed - United States, Texas ... More >> Trius Investigator Dallas, Texas, United States, 75247 Less <<
NCT01170221 Skin and Subcutaneous Tissue B... More >>acterial Infections Less << Phase 3 Completed - -
NCT01496677 Healthy Subjects Phase 1 Completed - United States, Florida ... More >> Trius Investigator Site 001 Daytona Beach, Florida, United States, 32117 Less <<
NCT00983255 Bacterial Infections Phase 1 Completed - United States, Wisconsin ... More >> Covance Clinical Research Unit Madison, Wisconsin, United States, 53704 Less <<
NCT01577459 Healthy Subjects Phase 1 Completed - United States, Kansas ... More >> Trius Investigator Site 001 Overland Park, Kansas, United States, 66212 Less <<
NCT01623401 Healthy Subjects Phase 1 Completed - United States, Texas ... More >> Trius Investigator Site 001 Dallas, Texas, United States, 75247 Less <<
NCT01519778 Major Cutaneous Abscess ... More >> Cellulitis Erysipelas Less << Phase 2 Completed - United States, California ... More >> Trius Investigator Site #118 Anaheim, California, United States, 92804 Trius Investigator Site #129 Buena Park, California, United States, 90620 Trius Investigator Site 103 Chula Vista, California, United States, 91911 Trius Investigator Site 105 La Mesa, California, United States, 91942 Trius Investigator Site #106 Long Beach, California, United States, 90813 Trius Investigator Site 104 Oceanside, California, United States, 92056 United States, Georgia Trius Investigator Site 101 Columbus, Georgia, United States, 31904 Trius Investigator Site 102 Savannah, Georgia, United States, 31406 United States, Nevada Trius Investigator Site 128 Las Vegas, Nevada, United States, 89109 United States, New Jersey Trius Investigator Site 115 Somers Point, New Jersey, United States, 08244 Less <<
NCT01170221 - Completed - -
NCT01539473 Healthy Volunteers Phase 1 Completed - United States, Indiana ... More >> Trius Investigator Site 001 Evansville, Indiana, United States, 47710 Less <<
NCT01967225 Skin Diseases, Infectious Phase 3 Completed - Japan ... More >> Nagakute, Aichi, Japan, 480-1195 Nagoya, Aichi, Japan, 455-8530 Nagoya, Aichi, Japan, 457-8510 Toyoake, Aichi, Japan, 470-1192 Yoshida, Fukui, Japan, 910-1193 Kasuga, Fukuoka, Japan, 816-0864 Kitakyushu, Fukuoka, Japan, 802-0077 Miyako-gun, Fukuoka, Japan, 800-0344 Sapporo, Hokkaido, Japan, 006-8555 Sapporo, Hokkaido, Japan, 060-0061 Amagasaki, Hyogo, Japan, 660-8511 Kobe, Hyogo, Japan, 650-0017 Inashiki-gun, Ibaraki, Japan, 300-0395 Tsukuba, Ibaraki, Japan, 305-8576 Kamakura, Kanagawa, Japan, 247-8533 Sagamihara, Kanagawa, Japan, 252-0375 Yokohama, Kanagawa, Japan, 231-8682 Koshi, Kumamoto, Japan, 861-1196 Tsu, Mie, Japan, 514-1101 Sendai, Miyagi, Japan, 983-8520 Nakagami-gun, Okinawa, Japan, 901-2393 Shimajiri, Okinawa, Japan, 901-0493 Hamamatsu, Shizuoka, Japan, 430-0929 Iwata, Shizuoka, Japan, 438-8550 Numazu, Shizuoka, Japan, 410-8555 Meguro-ku, Tokyo, Japan, 152-8902 Musashimurayama, Tokyo, Japan, 208-0011 Ota-ku, Tokyo, Japan, 143-0013 Ota-ku, Tokyo, Japan, 143-8541 Ota-ku, Tokyo, Japan, 145-0065 Setagaya-ku, Tokyo, Japan, 158-8531 Shinagawa, Tokyo, Japan, 141-8625 Shinjuku-ku, Tokyo, Japan, 162-8655 Tachikawa, Tokyo, Japan, 190-0014 Yonago, Tottori, Japan, 683-8605 Shimonoseki, Yamaguchi, Japan, 750-8520 Kofu, Yamanashi, Japan, 400-8506 Fukuoka, Japan, 810-0001 Gifu, Japan, 500-8513 Kochi, Japan, 781-8555 Kumamoto, Japan, 860-0008 Nagasaki, Japan, 852-8501 Osaka, Japan, 534-0021 Shizuoka, Japan, 420-8527 Shizuoka, Japan, 424-8636 Toyama, Japan, 930-0194 Less <<
NCT01271998 Bacterial Infection Phase 1 Completed - United States, Connecticut ... More >> Trius Investigator Site 001 Hartford, Connecticut, United States, 06102 Less <<
NCT01967225 - Completed - -
NCT00876655 Healthy Phase 1 Completed - United States, Texas ... More >> Covance Clinical Research Unit Austin, Texas, United States, 78752 Less <<
NCT03176134 Acute Bacterial Skin and Skin ... More >>Structure Infections Less << Phase 3 Not yet recruiting September 18, 2021 -
NCT01519778 - Completed - -
NCT00666601 Healthy Phase 1 Completed - United States, Florida ... More >> General Clinical Research Center Gainesville, Florida, United States, 32604 Less <<
NCT02019420 Pneumonia Phase 3 Completed - -
NCT02066402 Bacterial Infections Phase 3 Completed - -
NCT02477514 Skin Diseases, Bacterial Phase 1 Completed - -
NCT02991131 - Terminated(Company decision fo... More >>r 18299 TERMINATION status) Less << - Russian Federation ... More >> Multiple Locations, Russian Federation Singapore Multiple Locations, Singapore Less <<
NCT02276482 Skin Diseases, Infectious ... More >> Skin Diseases, Bacterial Less << Phase 3 Completed - -
NCT02066402 - Completed - -
NCT03378427 Prosthetic Joint Infection Not Applicable Recruiting January 15, 2020 France ... More >> GHU Garches Recruiting Garches, France, 92380 Contact: Aurélien DINH, M.D.    +33 (0)1 47 10 77 58    aurelien.dinh@aphp.fr    Hôpital de la Croix Rousse Recruiting Lyon, France, 69004 Contact: Tristan FERRY, M.D. Ph. D.    +33 (0)4 72 07 17 55    tristan.ferry@univ-lyon1.fr Less <<
NCT02444234 Cystic Fibrosis Phase 4 Completed - United States, California ... More >> University of Southern California Los Angeles, California, United States, 90089 Less <<
NCT02750761 Gram-Positive Bacterial Infect... More >>ions Less << Phase 1 Recruiting March 23, 2019 United States, Arkansas ... More >> Call for Information (Investigational Site 0124) Recruiting Little Rock, Arkansas, United States, 72202 United States, California Call for Information (Investigational Site 0109) Recruiting Los Angeles, California, United States, 90095 Call for Information (Investigational Site 0101) Recruiting Orange, California, United States, 92868 Call for Information (Investigational Site 0102) Recruiting San Diego, California, United States, 92123 United States, Colorado Call for Information (Investigational Site 0104) Recruiting Aurora, Colorado, United States, 80045 United States, Florida Call for Information (Investigational Site 0125) Recruiting Tampa, Florida, United States, 33606 United States, Kentucky Call for Information (Investigational Site 0113) Recruiting Louisville, Kentucky, United States, 40202 United States, Louisiana Call for Information (Investigational Site 0108) Recruiting Baton Rouge, Louisiana, United States, 70808 United States, Michigan Call for Information (Investigational Site 0107) Recruiting Detroit, Michigan, United States, 48201 United States, Missouri Call for Information (Investigational Site 0112) Recruiting Kansas City, Missouri, United States, 64108 Call for Information (Investigational Site 0133) Recruiting Saint Louis, Missouri, United States, 63110 United States, Texas Call for Information (Investigational Site 0129) Recruiting Fort Worth, Texas, United States, 76104 Call for Information (Investigational Site 0130) Recruiting Houston, Texas, United States, 77030 United States, Utah Call for Information (Investigational Site 0118) Recruiting Salt Lake City, Utah, United States, 84113 Colombia MDS Colombia SAS Recruiting Bogota, Colombia Contact: Liliana Ferro    57 12191093       Norway MSD Norge A/S Recruiting Drammen, Norway Contact: Katrin Moeschlin    46857813545       Ukraine MSD Ukraine LLC Recruiting Kiev, Ukraine Contact: Serhiy Mykhaylov    38 050 3107198       United Kingdom Merck Sharp & Dohme Ltd. Recruiting Hoddesdon, United Kingdom Contact: Paul Duffy    44 01992455265 Less <<
NCT02620787 Diabetes Woun... More >>d Infection Healthy Volunteers Less << Phase 1 Recruiting December 2017 United States, Connecticut ... More >> Hartford Hospital Recruiting Hartford, Connecticut, United States, 06102 Contact: David P Nicolau, PharmD    860-972-3941    david.nicolau@hhchealth.org    Contact: Arlinda Carr    860-972-6724    arlinda.carr@hhchealth.org    Principal Investigator: David P Nicolau, PharmD          Sub-Investigator: Joseph L Kuti, PharmD          Sub-Investigator: Ashley Shepard, MD          Sub-Investigator: James Nugent, MD Less <<
NCT02342418 Obesity Phase 4 Completed - -
NCT03746327 Prostheses Infection Phase 4 Not yet recruiting December 30, 2020 -
NCT03009045 Bone and Joint Infection PHASE2 COMPLETED 2021-08-06 Harbor-UCLA Medical Center, To... More >>rrance, California, 90502, United States|Los Angeles BioMedical Research Institute (LA BioMed), Torrance, California, 90502, United States Less <<
NCT03217565 Gram-Positive Infections Phase 1 Not yet recruiting August 3, 2021 -
NCT02342418 - Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.70mL

0.54mL

0.27mL

13.50mL

2.70mL

1.35mL

27.00mL

5.40mL

2.70mL

References

 

Historical Records

Categories